Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) went up by 12.20% from its latest closing price compared to the recent 1-year high of $38.94. The company’s stock price has collected 3.95% of gains in the last five trading sessions. Press Release reported 13 hours ago that Thinking about buying stock in Accolade, Vir Biotechnology, bluebird bio, Energy Focus, or Intercept Pharmaceuticals?
Is It Worth Investing in Intercept Pharmaceuticals Inc. (NASDAQ :ICPT) Right Now?
Plus, the 36-month beta value for ICPT is at 1.40. Opinions of the stock are interesting as 3 analysts out of 18 who provided ratings for Intercept Pharmaceuticals Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 11 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $29.53, which is $12.41 above the current price. ICPT currently public float of 24.38M and currently shorts hold a 35.27% ratio of that float. Today, the average trading volume of ICPT was 865.15K shares.
ICPT’s Market Performance
ICPT stocks went up by 3.95% for the week, with a monthly jump of 17.20% and a quarterly performance of -4.16%, while its annual performance rate touched -43.03%. The volatility ratio for the week stands at 7.61% while the volatility levels for the past 30 days are set at 7.56% for Intercept Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 3.93% for ICPT stocks with a simple moving average of -4.21% for the last 200 days.
Analysts’ Opinion of ICPT
Many brokerage firms have already submitted their reports for ICPT stocks, with B. Riley Securities repeating the rating for ICPT by listing it as a “Buy.” The predicted price for ICPT in the upcoming period, according to B. Riley Securities is $30 based on the research report published on January 11th of the current year 2022.
Goldman, on the other hand, stated in their research note that they expect to see ICPT reach a price target of $10, previously predicting the price at $17. The rating they have provided for ICPT stocks is “Sell” according to the report published on August 20th, 2021.
B. Riley Securities gave a rating of “Neutral” to ICPT, setting the target price at $18 in the report published on May 25th of the previous year.
ICPT Trading at -0.71% from the 50-Day Moving Average
After a stumble in the market that brought ICPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.78% of loss for the given period.
Volatility was left at 7.56%, however, over the last 30 days, the volatility rate increased by 7.61%, as shares surge +13.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.18% lower at present.
During the last 5 trading sessions, ICPT rose by +3.95%, which changed the moving average for the period of 200-days by -24.73% in comparison to the 20-day moving average, which settled at $16.29. In addition, Intercept Pharmaceuticals Inc. saw 3.31% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ICPT starting from AKKARAJU SRINIVAS, who purchase 147,000 shares at the price of $21.29 back on Mar 12. After this action, AKKARAJU SRINIVAS now owns 640,688 shares of Intercept Pharmaceuticals Inc., valued at $3,129,630 using the latest closing price.
AKKARAJU SRINIVAS, the Director of Intercept Pharmaceuticals Inc., purchase 90,000 shares at $20.96 during a trade that took place back on Mar 10, which means that AKKARAJU SRINIVAS is holding 493,688 shares at $1,886,622 based on the most recent closing price.
Stock Fundamentals for ICPT
Current profitability levels for the company are sitting at:
- -69.27 for the present operating margin
- +96.82 for the gross margin
The net margin for Intercept Pharmaceuticals Inc. stands at -87.91. The total capital return value is set at -42.98, while invested capital returns managed to touch -55.29. Equity return is now at value 59.10, with -20.00 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 1.53, with the company’s debt to enterprise value settled at 0.63. The receivables turnover for the company is 7.86 and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.